IDP Pharma has announced the first successful dosing of a human patient while targeting the cMyc protein. This protein's function is altered in approximately 70% of all tumors and is activated in most cancers.
There is an intrinsic connection between the cMyc protein and tumorigenesis (the production or formation of a tumor or tumors).
IDP Pharma's product, called IDP-121, is designed to impair cMyc protein function and selectively destroy the target.
This type of targeting is especially of interest to physicians treating hematological diseases such as multiple myeloma because myeloma is known to be cMyc dependent and this will give them the opportunity to quickly measure the on-target effect.
The team hopes to see success in both solid and liquid tumors.
The first patient was successful dosed in Murica, Spain, and will be monitored to see if this medication could potentially cause a major shift in disease management with the new target and mechanism of action. A multi-center, open-label Phase I/II clinical trial with more patients will now begin.
This trial will test the effectiveness of IDP-121 in treating cMyc-driven hematological malignancies, such as multiple myeloma. The trial will also include patients of non-Hodgkin lymphoma and CLL (chronic lymphocytic leukemia.
While much more research needs to be done in this field, it's exciting to know that more targets are being identified and drugs are being developed to treat multiple myeloma.
To learn more about this IDP-121-001 CASSANDRA clinical trial click here: IDP-121 Clinical Trial
To read more about this news release, read here: IDP Pharma announces first patient dosed in a Phase 1/2 Clinical Trial of IDP-121, a direct cMyc protein inhibitor and degrader
about the author
Audrey is the Editor for the HealthTree Foundation for Multiple Myeloma. She originally joined the HealthTree Foundation in 2020 as the Myeloma Community Program Director. While not knowing much about myeloma initially, she worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys iced chais from Dutch Bros. She also loves spending time with her supportive husband and energetic three-year-old.
More on New in Myeloma
ASH 2023 HealthTree 360° Blood Cancer Research Reception: Advancing Your Research Using HealthTree Data and Technology
Dec 07 / 18:00 PST